PSMA (prostate-specific membrane antigen) marker shows promise for kidney cancer applications
This article was originally published in Clinica
Executive Summary
Cytogen says that evidence is available that potentially expands the use of the prostate-specific membrane antigen (PSMA) tumour marker beyond prostate cancer assessment. According to the company, which markets a PSMA-targeting molecular imaging agent - PROSTASCINT - for detecting the extent and spread of prostate cancer, a new study has shown that the marker may provide a target for both imaging and therapeutic applications in kidney cancer. The findings, by US investigators from the Cleveland Clinic, in Ohio, demonstrated the expression of PSMA in cancer of the kidney; the study was presented last month at the American Urological Association annual meeting, in Atlanta, Georgia. The findings may help differentiate renal tumours and also evaluate possible recurrence in patients who undergo renal ablative procedures or partial nephrectomy for malignancy, said the Princeton, New Jersey firm.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.